Business Description
Orion Nutraceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA68629J2056
Share Class Description:
XCNQ:ORI: Ordinary SharesCompare
Compare
Traded in other countries / regions
ORI.Canada86OA.Germany IPO Date
2018-10-17Description
Orion Nutraceuticals Inc focuses on re-purposing a United States Food and Drug Administration approved drug to target asthma and chronic obstructive pulmonary disease (COPD).
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.57 | |||||
Equity-to-Asset | -1.15 | |||||
Debt-to-Equity | -0.19 | |||||
Debt-to-EBITDA | -0.43 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 67.2 | |||||
3-Year EPS without NRI Growth Rate | 67.1 | |||||
3-Year FCF Growth Rate | 56.9 | |||||
3-Year Book Growth Rate | 7.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.47 | |||||
Quick Ratio | 0.47 | |||||
Cash Ratio | 0.47 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -63.4 | |||||
Shareholder Yield % | -0.32 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | Neg. Equity | |||||
ROA % | 120.71 | |||||
ROIC % | -249.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 200 | |||||
PE Ratio without NRI | 40 | |||||
EV-to-EBIT | -44.6 | |||||
EV-to-EBITDA | -44.6 | |||||
EV-to-FCF | -539.48 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.6 | |||||
Earnings Yield (Greenblatt) % | -2.24 | |||||
FCF Yield % | -0.18 |